An interventional study of Educational Intervention and Quality-of-Life Assessment in Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma and Stage III Pancreatic Cancer AJCC v8, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Pancreatic Neoplasms by M.D. Anderson Cancer Center — 8 open to participants now, 23 under way, 2 of them phase 3. Pancreatic Neoplasms · M.D. Anderson Cancer Center.
Among the 66 studies in Pancreatic Neoplasms by M.D. Anderson Cancer Center, this one is the 32nd largest by enrollment of the 58 interventional ones that give a count, is one of 6 that started in 2021, is one of 10 with no phase, reaches primary completion later than 4 of the 22 other live ones, and was the 49th registered.
3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.
Browse Pancreatic Neoplasms studies →8 of the 66 studies in Pancreatic Neoplasms by M.D. Anderson Cancer Center are open now, in 4 countries. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 19+
M.D. Anderson Cancer Center · Sites in United States, Australia, Canada and 1 more country
Ages up to 17
By country, each count listing its studies:
Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 25 · Phase 3 3 · Phase 4 1
First in 1997; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 47 across 2,936 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 29 across the 58 interventional studies, 622 across the 8 observational. Of the 36 that completed or were terminated, 16 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
13 of the studies in Pancreatic Neoplasms by M.D. Anderson Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04484909M.D. Anderson Cancer CenterNBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer | 2026-12-31 |
| NCT04837118M.D. Anderson Cancer CenterResistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study | 2026-12-31 |
| NCT05053555M.D. Anderson Cancer CenterHigh Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies | 2027-01-31 |
| NCT05497778M.D. Anderson Cancer CenterA Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. | 2027-02-02 |
| NCT06651580M.D. Anderson Cancer CenterBiospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study | 2027-02-02 |
Add all 13 to your calendar (.ics) → With an account.
Among the 66 studies in Pancreatic Neoplasms by M.D. Anderson Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial studies the safety of a real-time tele-exercise resistance training (training done using a tablet) in maintaining skeletal muscle, strength, physical function, and health-related quality of life in patients with pancreatic cancer who are receiving combination chemotherapy or have undergone surgery for the treatment of pancreatic cancer. Tele-exercise resistance training may improve physical function and quality of life in patients with pancreatic cancer.
PRIMARY OBJECTIVE:
I. Evaluate the safety of a progressive, home-based, tele-exercise resistance training (tele-RT) intervention in patients undergoing first line FOLFIRINOX chemotherapy for advanced pancreatic ductal adenocarcinoma (PDAC) (Study 1) and in survivors who have undergone pancreatic cancer resection (Study 2).
SECONDARY OBJECTIVES:
I. Evaluate the feasibility and acceptability of the tele-RT intervention.
II. Evaluate changes in the following exploratory outcome measures over the course of first-line FOLFIRINOX for advanced PDAC and associations between resistance training (RT) volumes and their changes:
IIa. Muscular strength IIb. Muscular endurance IIc. Body composition (skeletal muscle mass) IId. Aerobic fitness IIe. Self-reported physical activity IIf. Self-reported physical functioning IIg. Fatigue IIh. Peripheral neuropathy IIi. Health-related quality of life (QOL) IIj. Completion of intended chemotherapy dose (Among patients who are undergoing chemotherapy; all participants in Study 1 and some in Study 2) IIk. Exercise motivation IIl. Exercise self-efficacy IIm. Social support for exercise IIn. Reduction or change in FOLFIRINOX treatment plan III. Evaluate cancer care providers' (treating physicians and other clinical personnel) perspectives regarding the feasibility and acceptability of the tele-RT intervention for their patients.
OUTLINE:
STUDY 1: During the first 2-3 months of first line FOLFIRINOX chemotherapy, patients complete at least 4 tele-RT sessions over 30-45 minutes each, every 2 weeks. Patients receive handouts created by MD Anderson Cancer Center (MDACC) clinical dietitians including individualized recommendations for daily protein intake and information about healthy protein supplementation during chemotherapy. Patient may also attend a visit with a registered dietician (or delegate dietician) per standard of care, if they have renal insufficiency, special dietary needs, or difficulty adhering to protein recommendations.
STUDY 2: After standard of care surgical resection, patients complete at least 4 tele-RT sessions over 30-45 minutes each, every 2 weeks for 2-3 months. Patients receive handouts created by MDACC clinical dietitians including individualized recommendations for daily protein intake and information about healthy protein supplementation during chemotherapy. Patient may also attend a visit with a registered dietician (or delegate dietician) per standard of care, if they have renal insufficiency, special dietary needs, or difficulty adhering to protein recommendations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SEE DETAILED DESCRIPTION.
Other: Educational Intervention · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Other: Resistance Training
Receive handouts containing dietary recommendations
Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational
Ancillary studies
Also known as: Quality of Life Assessment
Ancillary studies
Participate in a resistance training program
Also known as: Strength Training
Safety of the tele-resistance training (RT) program
Safety will be assessed based on the rate of musculoskeletal injuries and other adverse health events that participants incur while participating in tele-RT sessions. Participants will be monitored throughout the exercise intervention for musculoskeletal injuries and other adverse health events and referred to a Physical Medicine and Rehabilitation physician or their gastrointestinal (GI) Medical Oncology teams as necessary. The association of the injury with strength training will be assessed by asking participants to rate the injury on a scale of 1-4 (1=not related, 2=unlikely related, 3=likely related, 4=definitely related). The severity of the injury will be rated on a scale of 1-4 (1=mild/no change in daily activity, 2=some limitation of daily activity, 3=major limitation of daily activity, 4=life threatening). The duration for which daily activities were impacted will be rated on a scale from 1-5 (1=no change, 2=1-3 days, 3=4-7 days, 4=1-2 weeks, 5=more than 2 weeks).
Time frame: 3-4 months
Post-exercise muscle soreness
Soreness will be assessed at the beginning of each tele-RT session, with participants asked to describe how soreness has changed since the previous RT session and how soreness has changed over the course of RT sessions. If soreness is not becoming more manageable with ongoing RT, participants will be referred to Dr. Ngo-Huang (study co-principal investigator \[PI\] and physiatrist) for follow-up to rule out any underlying injuries.
Time frame: 3-4 months
Body composition
Cross-sectional areas (CSA) of skeletal muscle, intramuscular fat, visceral fat, and subcutaneous fat will be measured using SliceOMatic software (TomoVision, 2012) using computed tomography images routinely obtained for cancer assessment and staging purposes. Imaging dates will align with cancer staging and restaging appointments at T0 and T1. Cross-sectional areas at the L3 vertebral level will be standardized to the square of participants' heights in meters. Average radiodensity (in Hounsfield Units) of skeletal muscle will also be collected using SliceOMatic software.
Time frame: 3-4 months
Aerobic fitness
Will be measured using 6-minute walk test (6MWT) distance, measured in meters. For participants who undergo remote exercise testing, the 2-minute step test will be used to assess aerobic fitness. Participants will be guided to step in place as quickly as possible, raising each knee to the proper height (midway between the opposite knee and hip), with trainers recording the number of complete steps they can complete in 2 minutes.
Time frame: 3-4 months
Acceptability for Feasibility
Will be assessed with the following variables: 1)Uptake rate: Study enrollment will be considered feasible if 70% of eligible patients who are approached to consider study enrollment actually consent and enroll. 2) Study completion rate: If 70% of participants who complete T0 measures (fitness and survey measures) also complete measures at T1. 3) Tele-RT session attendance rate: If the rate of session completion is \>= 70%. 4) Adherence to prescribed exercise volume (sets x repetitions x resistance): If the volume of exercise completed is \>= 70% of the volume prescribed.
Time frame: 3-4 months
Acceptability for participants
Assessed with the Participant Evaluation of Feasibility and Acceptability questionnaire, adapted from Ingram, et al (2010). This questionnaire includes both Likert Scale and open-ended questions. Likert Scale items will be rated on 5-point scales (1=strongly disagree, 2=disagree, 3=neutral, 4=agree, 5=strongly agree). Acceptability will be assessed on an item-by-item basis and as an average item score, with scores \>= 4 ("agree" to "strongly agree") indicating acceptability. Responses to open-ended questions will be analyzed qualitatively to inform development of further iterations of the exercise intervention. Qualitative analysis will follow a content analysis strategy to systematically define units of text, quantify them, and group them into meaningful categories.
Time frame: 3-4 months
Acceptability for providers
Assessed with a brief program evaluation questionnaire distributed to all GI medical oncologists, GI surgeons, advanced practice providers, and clinical dietitians who are involved in participants' care and have some interaction with intervention personnel during recruitment, referral, scheduling, or follow up. Provider acceptability questionnaires will be distributed via REDCap immediately following collection of T1 data from the final study participant and will include Likert Scale items and open-ended items adapted from the Participant Evaluation of Feasibility and Acceptability.
Time frame: 3-4 months
Dynamic upper- and lower-body muscular strength
Strength in upper- and lower-body muscle groups will be measured using the following 1-repetition maximum (1RM) lifts: chest press, seated row, leg press, and leg extension. 1RM tests are considered the gold standard for assessing muscular strength in non-laboratory situations. 1RM tests are defined as the maximal weight that can be lifted once with correct lifting technique and are used by athletic trainers, health and fitness professionals and rehabilitation specialists to assess strength and to evaluate training programs. They will be performed in the following sequence, ordered from largest to smallest muscle groups and alternating between upper and lower body movements to allow for sufficient rest: leg press, chest press, leg extension, seated row.
Time frame: 3-4 months
Dynamic upper- and lower-body muscular endurance
Endurance of upper and lower body muscle groups as measured by the maximum number of repetitions performed at 70% of the T0 1RM for each of the following lifts: leg press, chest press, leg extension, seated row. Participants will rest sufficiently between movements and will perform tests in the same order that they performed 1RM testing. Participants who undergo remote enrollment and exercise testing will undergo the following exercise "field tests" to assess muscular strength and endurance: 1) 30-second chair stand test (to assess lower body strength and muscular endurance) and 30-second arm curl test (to assess upper body strength and muscular endurance).
Time frame: 3-4 months
Fatigue
Self-reported fatigue will be measured using the Functional Assessment of Cancer Therapy-Fatigue (FACT-F). The FACT-F consists of 13 fatigue-related items and has demonstrated validity and reliability as a brief, standalone measure of fatigue among cancer survivors. The FACT-F will provide a single score, with higher scores indicating better quality of life (QOL) (less fatigue). The FACT-F will be distributed and completed via REDCap at T0 and T1.
Time frame: 3-4 months
Chemotherapy-induced peripheral neuropathy (CIPN)
CIPN will be self-reported using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - CIPN-20 item scale. This is a 20-item questionnaire regarding sensory, motor, and autonomic neuropathy symptoms with each item scored from 1 (not at all) to 4 (very much), and all items are summed to result in a score range of 20 to 80. A higher score on the questionnaire indicates more symptom burden from CIPN. Will only administer and score items 1-19 with scores ranging from 16 to 76. This questionnaire will be distributed and completed via REDCap at T0 and T1.
Time frame: 3-4 months
Health-related QOL
Will be self-reported using the Functional Assessment of Cancer Therapy-Hepatobiliary questionnaire (FACT-Hep). The FACT-Hep is composed of two parts: the 27-question FACT General (FACT-G) and the 18-question Hepatobiliary Subscale (HS). The FACT-G measures cancer-related QOL in four domains: physical, social/family, emotional, and functional well-being. The HS evaluates the severity of hepatobiliary cancer-specific symptoms. All questions are scored on a Likert scale from 0 to 4 (some are reversed) and added to create FACT-G and HS scores, and these are added to create a FACT-Hep score. A higher FACT-G subscore denotes better QOL. A higher HS subscore denotes a lower degree of disease-related symptoms. The FACT-Hep will be distributed and completed via REDCap at T0 and T1.
Time frame: 3-4 months
Chemotherapy tolerance and delivery
Chemotherapy tolerance will be assessed based on relative dose intensities (RDI; defined as the ratio of administered cumulative dose over planned cumulative dose) of the 4 drugs comprising the FOLFIRINOX regimen (39). These data will be collected from participants' electronic health records. Will record if there are any changes in the prescribed regimen (reduction in dose or change in medications) during the study period.
Time frame: 3-4 months
Exercise motivation
Will be measured using Behavioral Regulation in Exercise Questionnaire-Version 3 (BREQ-3). The BREQ-3 has subscales measuring external (i.e., performed because of an outside demand or potential reward), introjected (i.e., performed to demonstrate an ability), identified (i.e., consciously valuing exercise), and intrinsic forms of exercise behavior regulation. Participant responses will be evaluated as separate subscale scores and as an overall score, with higher overall scores indicating higher relative autonomy in exercise regulation (i.e., higher personal valuation of exercise and higher intrinsic motivation to exercise). The BREQ-3 will be distributed and completed via REDCap at T0 and T1.
Time frame: 3-4 months
Exercise barriers self-efficacy
Participants will complete the Barriers Self-efficacy survey developed by Marcus et al. and adapted by Tirado-Gomez et al. This survey includes 14 questions that assess how confident an individual is in his or her ability to exercise when facing various barriers, such as sickness, fatigue, and lack of time. Participants will indicate their level of confidence using a scale ranging from 1 (not at all confident) to 5 (extremely confident). Responses to the 14 individual items will be summed to obtain an overall score, with a range of 14 to 70.
Time frame: 3-4 months
Social support for exercise
Social support for exercise from family and friends will be measured using the Social Support for Exercise Survey (SSES). The SSES lists 13 items that family members or friends may do or say to someone who is trying to exercise regularly, from providing emotional support. The SSES also captures social influences that may hinder exercise. Patients responded to each item separately for friends and family, scoring each item on a Likert-like scale from 1=none to 5=very often. Scores for family and friend participation and family rewards and punishment will be computed following published protocols. Participants will also complete the 13 item scale regarding perceived social support from study interventionists/staff, with instructions to record "does not apply" for items such as "planned for exercise on recreational outings" and "helped plan activities around my exercise." The SSES will be distributed and completed via REDCap at T0 and T1.
Time frame: 3-4 months
Self-reported physical activity
Measured using a modified version of the Godin-Shephard Leisure Time Physical Activity Questionnaire (GLTPAQ). The GLTPAQ will be modified as in Vallerand, et al. (2017) to include both aerobic exercise and strengthening exercise related questions and to ascertain performance of guideline-concordant physical activity. To reflect current exercise recommendations, patients will be instructed to include any exercise that lasted at least 5 minutes. Additionally, we will include a single item that asks how many times per week participants perform strengthening exercise (i.e., exercise that improves muscular strength such as weight lifting, resistance bands, sit ups, or push-ups). This question will be extracted from the Health Information National Trends Survey (HINTS) conducted by the National Cancer Institute.
Time frame: 3-4 months
Self-reported physical functioning
Self-reported physical functioning will be measured using the Patient Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 - Physical Function 12a. The instrument consists of 12 questions assessing respondents' abilities to perform physical tasks and activities of daily living. Items are scored on 5-point Likert scales, with higher scores indicating higher physical functioning. The PROMIS will be distributed and completed via REDCap at T0 and T1.
Time frame: 3-4 months
Feasibility of Automated Self Assisted 24-hour recall (ASA24) (24-hour dietary recall)
Will be assessed by determining the proportion of participants who complete the survey at each target assessment. We will measure the adoption of nutrition recommendations by comparing the recall responses from within the study period to their baseline responses at the time of enrollment. Will also compare adherence to our nutrition recommendations (i.e., protein intake) through the ASA-24 survey at each targeted assessment.
Time frame: At time of enrollment up to 7-10 days before date of surgery
PDFs hosted by the registry, ClinicalTrials.gov.
Started Feb 2021 (actual). Primary completion is estimated for Dec 2026, 70 months after the start.
Of 405 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 70 months is above that.
Counting every sponsor, half of 432 studies reached it within 44 months; a quarter within 26 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.